Cargando…

HE4 is a novel tissue marker for therapy response and progestin resistance in medium- and low-risk endometrial hyperplasia

Mostrar otras versiones (1)

Detalles Bibliográficos
Autores principales:	Ørbo, Anne, Arnes, Marit, Lyså, Lena Myreng, Borgfeldt, Christer, Straume, Bjørn
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2016
Materias:	Corrigendum
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5117800/ https://www.ncbi.nlm.nih.gov/pubmed/27711084 http://dx.doi.org/10.1038/bjc.2016.330

Ejemplares similares

HE4 is a novel tissue marker for therapy response and progestin resistance in medium- and low-risk endometrial hyperplasia
por: Ørbo, Anne, et al.
Publicado: (2016)

Relapse risk of endometrial hyperplasia after treatment with the levonorgestrel‐impregnated intrauterine system or oral progestogens
por: Ørbo, A, et al.
Publicado: (2015)

Levonorgestrel-impregnated intrauterine device as treatment for endometrial hyperplasia: a national multicentre randomised trial*
por: Ørbo, A, et al.
Publicado: (2014)

Progestin Resistance and Corresponding Management of Abnormal Endometrial Hyperplasia and Endometrial Carcinoma
por: Lv, Mu, et al.
Publicado: (2022)

Corrigendum to “Expression of HE4 in Endometrial Cancer and Its Clinical Significance”
por: Li, Xiao, et al.
Publicado: (2018)

Progestin plus metformin improves outcomes in patients with endometrial hyperplasia and early endometrial cancer more than progestin alone: a meta-analysis
por: Shao, Fengping, et al.
Publicado: (2023)

Progestin Intrauterine Devices and Metformin: Endometrial Hyperplasia and Early Stage Endometrial Cancer Medical Management
por: Nwanodi, Oroma
Publicado: (2017)

Identification of Genes and Pathways Differentially Expressed in Progestin Responsive Endometrial Cancer and Hyperplasia
por: Gertz, Jay, et al.
Publicado: (2021)

Corrigendum to “Prediction of Endometrial Hyperplasia and Cancer among Premenopausal Women with Abnormal Uterine Bleeding”
por: Giannella, Luca, et al.
Publicado: (2020)

Long-term outcomes of progestin plus metformin as a fertility-sparing treatment for atypical endometrial hyperplasia and endometrial cancer patients
por: Mitsuhashi, Akira, et al.
Publicado: (2019)

Fertility-preserving treatment in complex atypical hyperplasia and early endometrial cancer in young women with oral progestin: Is it effective?
por: Baek, Ji Sun, et al.
Publicado: (2016)

Comparison of diagnostic accuracy between endometrial curettage and aspiration biopsy in patients treated with progestin for endometrial hyperplasia: a Korean Gynecologic Oncology Group study
por: Kim, Mi Kyoung, et al.
Publicado: (2020)

Prominent decidualization following progestin treatment for endometrial hyperplasia and carcinoma as a mimic of large residual tumor: A cautionary tale
por: Hu, Yang, et al.
Publicado: (2021)

Characteristics of progestin-insensitive early stage endometrial cancer and atypical hyperplasia patients receiving second-line fertility-sparing treatment
por: Zhou, Shuang, et al.
Publicado: (2021)

Efficacy of Oral Medications or Intrauterine Device-Delivered Progestin in Patients with Endometrial Hyperplasia with or without Atypia: A Network Meta-Analysis
por: Zhang, Yu-Fei, et al.
Publicado: (2023)

High preoperative blood levels of HE4 predicts poor prognosis in patients with ovarian cancer
por: Kalapotharakos, Grigorios, et al.
Publicado: (2012)

Identification of potential models for predicting progestin insensitivity in patients with endometrial atypical hyperplasia and endometrioid endometrial cancer based on ATAC-Seq and RNA-Seq integrated analysis
por: Hu, Jia-Li, et al.
Publicado: (2022)

A multiplex biomarker assay improves the diagnostic performance of HE4 and CA125 in ovarian tumor patients
por: Leandersson, Pia, et al.
Publicado: (2020)

Identification and characterization of endometrial carcinoma with tumor markers HE4 and CA125 in serum and endometrial tissue samples
por: Cuesta-Guardiola, Tatiana, et al.
Publicado: (2021)

Response to comment on: Comparison of diagnostic accuracy between endometrial curettage and aspiration biopsy in patients treated with progestin for endometrial hyperplasia: a Korean Gynecologic Oncology Group study
Publicado: (2020)

Baseline Serum HE4 But Not Tissue HE4 Expression Predicts Response to the Levonorgestrel-Releasing Intrauterine System in Atypical Hyperplasia and Early Stage Endometrial Cancer
por: Behrouzi, Roya, et al.
Publicado: (2020)

Letter to editor in response to: Comparison of diagnostic accuracy between endometrial curettage and aspiration biopsy in patients treated with progestin for endometrial hyperplasia: a Korean Gynecologic Oncology Group study
Publicado: (2020)

Combined estrogen-progestin pill is a safe and effective option for endometrial hyperplasia without atypia: a three-year single center experience
por: Wang, Yang, et al.
Publicado: (2019)

Corrigendum to ‘Antihypertensive treatment with telmisartan in a cat with amlodipine-induced gingival hyperplasia’
Publicado: (2022)

Nogo-B promotes the epithelial-mesenchymal transition in HeLa cervical cancer cells via Fibulin-5
por: Xiao, Wei, et al.
Publicado: (2022)

Corrigendum to “Single-cell profiling of low-stage endometrial cancers identifies low epithelial vimentin expression as a marker of recurrent disease” [EBioMedicine 92 (2023) 104595]
por: Lien, Hilde E., et al.
Publicado: (2023)

The safety and efficacy of aspirin intake in photoselective vaporization laser treatment of benign prostate hyperplasia [Corrigendum]
Publicado: (2013)

siRNA-mediated inhibition of endogenous brain-derived neurotrophic factor gene modulates the biological behavior of HeLa cells
por: Sun, Chun-Yan, et al.
Publicado: (2021)

Corrigendum for “Adverse Outcomes and Economic Burden of Congenital Adrenal Hyperplasia Late Diagnosis in the Newborn Screening Absence”
Publicado: (2021)

Dual progestin therapy for fertility-sparing treatment of grade 2 endometrial adenocarcinoma
por: Newtson, A.M., et al.
Publicado: (2017)

Progestins Related to Progesterone and Testosterone Elicit Divergent Human Endometrial Transcriptomes and Biofunctions
por: Houshdaran, Sahar, et al.
Publicado: (2020)

Chlorpromazine Sensitizes Progestin-Resistant Endometrial Cancer Cells to MPA by Upregulating PRB
por: Cui, Yunxia, et al.
Publicado: (2021)

Corrigendum: Endometrial receptivity enhancement through induced injury and repair during ovarian stimulation: the Receptivity Enhancement by Follicular-phase Renewal after Endometrial ScratcHing (REFRESH) trial protocol
por: Santos-Ribeiro, Samuel, et al.
Publicado: (2020)

Correction to: Chen, Chen, Ling, Lin, He, and Guan, Investigation of optimum N-terminal probrain natriuretic peptide level in patients on maintained hemodialysis
Publicado: (2017)

Increased incidence and improved survival in endometrial cancer in Sweden 1960–2014: a population-based registry survey
por: Herbst, Filip, et al.
Publicado: (2023)

BMI-1 promotes invasion and metastasis in endometrial adenocarcinoma and is a poor prognostic factor
por: Yu, Jing, et al.
Publicado: (2022)

Fibroblast Growth Factor Receptor 2 Isoforms Detected via Novel RNA ISH as Predictive Biomarkers for Progestin Therapy in Atypical Hyperplasia and Low-Grade Endometrial Cancer
por: Sengal, Asmerom T., et al.
Publicado: (2021)

Corrigendum to “The Effects of Cytokines in Adipose Stem Cell-Conditioned Medium on the Migration and Proliferation of Skin Fibroblasts In Vitro”
por: Zhao, Jiajia, et al.
Publicado: (2016)

Corrigendum: Acknowledgments. Effect of Photoselective Vaporization Prostatectomy on Lower Urinary Tract Symptoms in Benign Prostatic Hyperplasia With or Without Intravesical Prostatic Protrusion
por: Kim, Myung Soo, et al.
Publicado: (2013)

Recurrent Endometrial Stromal Sarcoma: Treatment with a Progestin and Gonadotropin Releasing Hormone Agonist
por: duPont, Nefertiti Chianti, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_ku9jfo638nmtpgbuhcuvilv4c5